Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 6,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Ricin Poisoning
Interventions: RVEc; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: HIV Infections
Interventions: Cognitive behavioral coping effectiveness training, Standard care, Single group workshop on coping effectiveness training; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Bowel Obstruction
Interventions: IV morphine sulfate or Sponsor-approved equivalent, EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 3 more

Conditions: Tobacco Use Disorder
Interventions: active repetitive transcranial magnetic stimulation, sham repetitive transcranial magnetic stimulation, cognitive behavioral therapy for smoking cessation, nicotine replacement therapy; Device · Behavioral · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain
Interventions: Preservative Free Lidocaine, Saline; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 7 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Pain, Hip Fractures
Interventions: Femoral Nerve Block; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: New York, New York

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Stem cell (HPC) implantation, Stereotactic surgical device; Biological · Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: Propranolol or Carvedilol, Atenolol, Bisoprolol or Sotalol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 817,337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Migraine
Interventions: Daily questionnaire; Other
Lead sponsor: Theranica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2030
U.S. locations: 3
States / cities: Westport, Connecticut • Ridgeland, Mississippi • Poughkeepsie, New York

Conditions: Alcohol Dependence, Alcohol Abuse
Interventions: Naltrexone, Brenda Therapy Sessions, Placebo; Drug · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Fractures, Closed, Pain, Postoperative, Pain Catastrophizing, Pain, Acute, Analgesia, Opioid Use, Acceptance and Commitment Therapy, Orthopedics, Analgesics, Opioid, Text Messaging
Interventions: Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot; Behavioral
Lead sponsor: Christopher Anthony; Other
Eligibility: 18 Years to 100 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Depression
Interventions: Problem Solving Therapy (PST), Medication Management; Behavioral
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anesthesia, Neuromuscular Blockade
Interventions: Saline 0.06 ml/kg, Rocuronium 0.2 mg/kg, Rocuronium 0.4 mg/kg, Rocuronium 0.6 mg/kg; Drug
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Persistent Depressive Disorder
Interventions: Behavioral Activation for return to work; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Weight Gain
Interventions: Control, LCD; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy Volunteers, Pharmacologic Action
Interventions: Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cocaine Use Disorder
Interventions: Prize-Based Contingency Management, Treatment As Usual Outpatient Substance Use Treatment; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatic Impairment
Interventions: Hydrocodone bitartrate extended-release tablet; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Systemic Sclerosis
Interventions: Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: ADHD
Interventions: Attention Deficit Hyperactivity Disorder Treatment Decision Aid; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Yellow Fever (Healthy Volunteers)
Interventions: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine, Yellow fever vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: HIV
Interventions: SUCCESS-E, Enhanced Standard of Care, Key Informant Interviews; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Search by objective public record fields.

ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ - 3-Dose Primary Series With Boost

Effectiveness of Coping Training for People With HIV Experiencing Treatment Side Effects (The Balance Project)

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy

Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD

The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast:

Improving Pain and Function in Hip Fracture

CNS10-NPC-GDNF for the Treatment of ALS

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol

Observational Study to Assess Migraine Prediction Tool

Sweet Preference and Alcohol Craving

Pain and Narcotic Usage After Orthopaedic Surgery

Improving Depression Treatment for Older Minority Adults

The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy

Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning

Impact of a LCD on Metabolic Inflexibility and Cardiovascular Risk in Liver Transplant Patients

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project

A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Refining the Shared Decision Making Process Survey in ADHD Medication Decisions

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

Substance Use and HIV Action for Reentry and Engagement.

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis